Iribarren C, Rothman KJ, Bradley MS, Carrigan G, Eisner MD, Chen H. Cardiovascular and cerebrovascular events among patients receiving omalizumab: pooled analysis of patient-level data from 25 randomized, double-blind, placebo-controlled clinical trials. J Allergy Clin Immunol. 2017 May;139(5):1678-80. doi: 10.1016/j.jaci.2016.12.953

CAPSULE SUMMARY: Among patients who participated in randomized clinical trials of omalizumab, no substantial overall increase in the risk of cardiovascular events was observed in the treatment arms compared with placebo.

Share on: